GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction.

Nat Rev Gastroenterol Hepatol · 2024

Last updated 2026-05-28

Journal	Nat Rev Gastroenterol Hepatol, 2024
Citations	6
Relative citation ratio	0.91
NIH percentile	47
Molecules	—
Conditions studied	Type 2 Diabetes, Obesity, Cardiovascular Risk Reduction, Chronic Kidney Disease, Mash, Obstructive Sleep Apnea, Pcos

Full record and abstract on PubMed 39242961 ↗